Overall, the tumour suppressive activity of its substrates and the overexpression of βTrCP observed using in vitro and in vivo models, and in human cancers support a role in tumorigenic activity, so it may be a potential target for cancer therapeutics [24]. Here, BTRC is linked to neoplasm.